RT Journal Article
T1 Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population
A1 Fernandez-Mateos, J.
A1 Seijas-Tamayo, R.
A1 Mesia, R.
A1 Taberna, M.
A1 Pastor Borgonon, M.
A1 Perez-Ruiz, E.
A1 Klain, J. C. Adansa
A1 Vazquez Fernandez, S.
A1 del Barco Morillo, E.
A1 Lozano, A.
A1 Gonzalez Sarmiento, R.
A1 Cruz-Hernandez, J. J.
A1 Spanish Head Neck Canc Cooperative, 
K1 Head and neck squamous cell carcinoma (HNSCC)
K1 Epidermal growth factor receptor (EGFR)
K1 Polymorphism
K1 SNP
K1 EGFR
K1 CCDN1
K1 FCGR2A
K1 FCGR3A
K1 KRAS-LCS6
K1 Cetuximab
K1 Toxicity
K1 Platinum-based chemotherapy
K1 Phase-ii
K1 Plus cetuximab
K1 Skin toxicity
K1 Single-agent
K1 Lung-cancer
K1 Open-label
K1 Risk
K1 Epidemiology
K1 Combination
AB Objectives: To examine the relationship between polymorphisms of the epidermal growth factor receptor (EGFR) pathway and toxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with cetuximab.Material and methods: Multicenter, retrospective, observational pilot study which included 110 patients with histologically-confirmed human papillomavirus (HPV) negative HNSCC in locally advanced stages (III-IVA-B) and who were treated with chemotherapy and radiotherapy plus cetuximab between 2003 and 2013. Genetic analyses for single nucleotide polymorphisms (SNP) in genes EGFR, CCDN1, FCGR2A, FCGR3A and KRAS-LCS6 were performed though available allelic discrimination assay and/or polymerase chain reaction-restriction fragment length polymorphism methods.Results: Acneiform rash was observed in 55.5% of patients, dry skin in 45.5% and pruritus in 20.9%. A significant association with dry skin and global cetuximab-related toxicity was observed for the KRAS-LCS6 (rs61764370) variant (p
PB Elsevier science bv
SN 1368-8375
YR 2016
FD 2016-12-01
LK https://hdl.handle.net/10668/26658
UL https://hdl.handle.net/10668/26658
LA en
DS RISalud
RD Apr 20, 2025